NCT01752569 (SCART) is a Phase 1, PHASE2 clinical trial of Selumetinib in AIDS-related Kaposi's Sarcoma, sponsored by Sheffield Teaching Hospitals NHS Foundation Trust.

Who is sponsoring NCT01752569?

NCT01752569 is sponsored by Sheffield Teaching Hospitals NHS Foundation Trust.

What drugs are being tested in NCT01752569?

Interventions in NCT01752569: Selumetinib.

What condition does NCT01752569 study?

NCT01752569 studies AIDS-related Kaposi's Sarcoma.

Is NCT01752569 still recruiting?

NCT01752569 is currently terminated. Last updated 20 February 2019.

Last reviewed 2019-02-20 · How we verify

NCT01752569: SCART

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Selumetinib in Patients With Kaposi's Sarcoma

Terminated Phase 1, PHASE2 Last updated 20 February 2019

What this trial tests

Phase 1, PHASE2 trial testing Selumetinib in AIDS-related Kaposi's Sarcoma in 19 participants. Terminated before completion.

Timeline

15 June 2012

Primary endpoint
30 September 2015

20 December 2017

Quick facts

Lead sponsor	Sheffield Teaching Hospitals NHS Foundation Trust
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	19
Start date	15 June 2012
Primary completion	30 September 2015
Estimated completion	20 December 2017
Sites	6 locations across United Kingdom

Drugs / interventions tested

Selumetinib — full drug profile →

Conditions studied

AIDS-related Kaposi's Sarcoma — all drugs for AIDS-related Kaposi's Sarcoma →

Sponsor

Sheffield Teaching Hospitals NHS Foundation Trust

Who can join

18 and older, any sex, with AIDS-related Kaposi's Sarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cancer is a leading cause of death in individuals living with human immunodeficiency virus (HIV), and Kaposi's sarcoma (KS) remains the commonest HIV-associated cancer. KS is caused when individuals become infected with both HIV and another virus, Human herpesvirus-8 (HHV-8). Laboratory studies have shown that HHV-8 can stimulate biological pathways within KS lesions which promotes their growth. Selumetinib targets these pathways and may therefore be a useful new therapy for KS. Phase I of this trial aims to identify the best dose for the use of selumetinib and investigate the effects of selumetinib treatment on the anti-viral treatment HIV patients receive to control HIV infection. Phase II of this trial will investigate how well selumetinib works as a treatment for KS at the best dose determined in phase I.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

The MAPK pathway across different malignancies: a new perspective.
Burotto M, Chiou VL, Lee JM, Kohn EC. · · 2014 · cited 773× · PMID 24948110 · DOI 10.1002/cncr.28864
Kaposi sarcoma herpesvirus-associated cancers and related diseases.
Goncalves PH, Ziegelbauer J, Uldrick TS, Yarchoan R. · · 2017 · cited 130× · PMID 27662501 · DOI 10.1097/coh.0000000000000330
Evolving Paradigms in HIV Malignancies: Review of Ongoing Clinical Trials.
Bender Ignacio RA, Lin LL, Rajdev L, Chiao E. · · 2018 · cited 9× · PMID 30099376 · DOI 10.6004/jnccn.2018.7064
Selumetinib in Combination with Anti Retroviral Therapy in HIV-associated Kaposi sarcoma (SCART): an open-label, multicentre, phase I/II trial.
Young RJ, Kirkham A, Savage J, Gaskell C, et al · · 2025 · PMID 40108492 · DOI 10.1186/s12885-025-13890-x

Verify or expand the search:

Other trials of Selumetinib

Trials testing the same drug.

NCT06735820 — Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST · Phase 1, PHASE2 · not yet recruiting
NCT06188741 — Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 · Phase 2 · recruiting
NCT06763315 — Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese Children · Phase 2 · not yet recruiting
NCT06621082 — The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate Capsule · Phase 2 · not yet recruiting
NCT06620354 — Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule · Phase 2 · not yet recruiting

Other Sheffield Teaching Hospitals NHS Foundation Trust trials

Trials by the same sponsor.

NCT07407712 — Better Outcomes Through Optimal Sleep in Surgical Training · NA · recruiting
NCT07172555 — Virtual Dietetic Interventions in Patients With Coeliac · NA · recruiting
NCT06310993 — Exercise to Boost Immunity in Advanced Cancer · NA · not yet recruiting
NCT06905405 — The Use of Advanced Imaging in HFpEF · recruiting
NCT06633627 — Neurological Responses in Patients with Dentine Hypersensitivity · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01752569 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sheffield Teaching Hospitals NHS Foundation Trust
Last refreshed: 20 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01752569.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing